135 results
DEFA14A
VIR
Vir Biotechnology Inc
6 Apr 20
Additional proxy soliciting materials
4:53pm
Materials
Soliciting Material Pursuant to §240.14a-12
Vir Biotechnology, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s … with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which
DRS
EX-10.59
VIR
Vir Biotechnology Inc
23 Jun 20
Draft registration statement
12:00am
Information
Page 2 of 7
Raw Material Fees. WuXi Biologics will purchase the [***] (“Raw Materials”) from qualified vendors in accordance … with the Commercial QAG. The actual cost of purchased Raw Materials [***] in the Commercial MSA. The Raw Material pass-through costs [***].
Table 2
S-1
EX-10.21
VIR
Vir Biotechnology Inc
3 Sep 19
IPO registration
4:40pm
Addendum”).
1.5
OHSU may, fromtime-to-time include certain biological materials related to the Inventions, to this Agreement through the execution … to Section 6.2 of the Agreement.
2.9
“Confidential Information” means all information and materials provided by one Party (“Disclosing Party
DRS
EX-10.56
VIR
Vir Biotechnology Inc
23 Jun 20
Draft registration statement
12:00am
, including internal staff time, labor and materials costs and any testing, inspections and certifications required with respect to such modifications … [***].
1.44 “High-Value Materials” means all (i) bulk chromatography resins, (ii) Drug Substance in API form when used in the Manufacturing of Drug
DRS/A
EX-10.35
ig4 qvzyo6myt
7 Aug 19
Draft registration statement (amended)
12:00am
DRS
EX-10.57
d6t8o
23 Jun 20
Draft registration statement
12:00am
S-1
EX-10.35
q3c7yzf
3 Sep 19
IPO registration
4:40pm
DEFA14A
3wdbu5pz
6 Apr 21
Additional proxy soliciting materials
4:07pm
S-1
EX-10.42
fxd0bf3 r8eo
3 Sep 19
IPO registration
4:40pm
DRS
EX-10.42
45amdv
27 Jun 19
Draft registration statement
12:00am
DEFA14A
02ot2ge v2s0zakmfe
8 May 20
Additional proxy soliciting materials
4:10pm
DRS/A
EX-10.33
41mo6fr g8e
7 Aug 19
Draft registration statement (amended)
12:00am
8-K
EX-99.1
m7xrmo9lyqvgu7nublh
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
DRS/A
EX-10.34
m5rjaqbq07r0p7
7 Aug 19
Draft registration statement (amended)
12:00am